Schematic showing conceptual model of potential mode of BCG action and the expected effect of STING pathway activation to increase chemokine secretion and immune cell recruitment. From: Koti, et al., Bladder Cancer, vol. 5, no. 3, pp. 225–234, 2019

Systematic review of predictive molecular biomarkers associated with response to PD-1 and PD-L1 inhibitors. The visual illustrates the immune checkpoint blockade in advanced bladder cancer ranking the predictive value. From: Tu, et al., Bladder Cancer, vol. 5, no. 2, pp. 131–145, 2019

Clinical development of fibroblast growth factor receptor 3 (FGFR3) inhibitors for the treatment of urothelial cancer. The visual illustrates the dimerization of FGFR leading to the phosphorylation of the tyrosine kinase domains. From: Ibrahim, et al., Bladder Cancer, vol. 5, no. 2, pp. 87–102, 2019

This study covers patients’ experiences with treatment choice, surgical care, and recovery across health settings. Understanding patient experiences is essential to closing care gaps and developing patient-reported measures. From: McMullen, et al., Bladder Cancer, vol. 5, no. 1, pp. 51–61, 2019

This study gives an overview of the origin, pathological and molecular characteristics of commonly used human, murine and canine BC cell lines. The Venn diagram illustrates the human bladder cancer cell lines analyzed. From: TCM Zuiverloon et al., Bladder Cancer, vol. 4, no. 2, pp. 169–183, 2018

The synergistic relationship between immunotherapy and radiation. From Buchwald and Efstathiou. Bladder Cancer, vol. 1, no. 1, pp. 15–27, 2016

Bladder Cancer is classified as the official journal of the Bladder Cancer Advocacy Network (BCAN). Read more about this new partnership to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities via: tiny.cc/BLC-BCAN_PR

Welcome to the Bladder Cancer website! Please take a look around at the content of the journal and other features of this community portal, including joining the discussion thread about the latest challenging cases, or taking a look at the Clinical Trials Corner.